Glibenclamide in patients with poorly controlled type 2 diabetes: a 12-week, prospective, single-center, open-label, dose-escalation study

Virendra Rambiritch,1 Breminand Maharaj,2 Poobalan Naidoo3 1Biomedical Research Ethics Committee, University of Kwazulu-Natal, Durban, KwaZulu-Natal, South Africa; 2Department of Therapeutics and Medicines Management, University of Kwazulu-Natal, Durban, KwaZulu-Natal, South Africa; 3Boehringer-Ing...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Rambiritch V, Maharaj B, Naidoo P
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2014
Materias:
Acceso en línea:https://doaj.org/article/afefd090cba3450398af0fbe2ce5d64a
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares